Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Adma Biologics (ADMA) Q3 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.01 per share a year ago.
Did ADMA Biologics (ADMA) Commit Securities Fraud Resulting in 20% Stock Drop? Contact BFA Law about its Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
ADMA Biologics Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ADMA STOCK ALERT: Why is ADMA Biologics Under Investigation for Securities Fraud? Contact BFA Law if You Lost Money on Your Investment (Nasdaq:ADMA)
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into ADMA Biologics, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.
ADMA STOCK NEWS: ADMA Biologics is Under Investigation for Securities Fraud after Stock Dropped 20%; Contact BFA Law if You Suffered Losses (Nasdaq:ADMA)
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q3 Earnings?
ADMA is having a stupendous run in 2024 so far on strong performance of Asceniv and high growth prospects.
Adma Biologics (ADMA) Soars 18.8%: Is Further Upside Left in the Stock?
Adma Biologics (ADMA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Did ADMA Biologics Commit Securities Fraud Resulting in 20% Stock Drop? Contact BFA Law about its Ongoing Securities Fraud Investigation (Nasdaq:ADMA)
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ADMA INVESTIGATION NOTE: Contact BFA Law about ADMA Biologics Securities Fraud Investigation into Auditor Resignation (Nasdaq:ADMA)
NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting Click Here
